KYinno
Kyinno is a leading preclinical contract research organization (CRO) specializing in customized in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery services. The company leverages proprietary assets including over 3000 engineered cell lines, bispecific and tri-specific antibody discovery mouse models, a 5000-antibody specificity screening MPSA-AB5000 panel, and the KY-AI antibody development platform. Founded in 2017, Kyinno operates a 5000m² laboratory and a strategic business hub in Boston, serving over 1,000 partners globally, including biotech startups and multinational pharmaceutical corporations. With a team of 130 professionals, Kyinno focuses on advancing cancer drug discovery and development through innovative technologies and comprehensive preclinical services.
KYinno
Kyinno is a leading preclinical contract research organization (CRO) specializing in customized in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery services. The company leverages proprietary assets including over 3000 engineered cell lines, bispecific and tri-specific antibody discovery mouse models, a 5000-antibody specificity screening MPSA-AB5000 panel, and the KY-AI antibody development platform. Founded in 2017, Kyinno operates a 5000m² laboratory and a strategic business hub in Boston, serving over 1,000 partners globally, including biotech startups and multinational pharmaceutical corporations. With a team of 130 professionals, Kyinno focuses on advancing cancer drug discovery and development through innovative technologies and comprehensive preclinical services.